Key result
Polypharmacy linked to potential drug-drug interactions affecting ~69% of admitted psychiatric patients.
Why the study?
Combined medications can result in life-threatening potential drug-drug interactions causing severe clinical outcomes, prompting the evaluation of their prevalence and associated factors among admitted psychiatric patients.
Population
325 admitted patients with psychiatric disorders in Northwest Ethiopia
Design
Institution-based multicenter cross-sectional study
Authors
Loading...
May inform pDDI screening in psychiatric inpatients; leaves open whether interventions reduce adverse events.
Cross-Sectional (n=325)
Yes
A high prevalence (68.9%) of clinically significant potential drug-drug interactions was found among admitted psychiatric patients, driven by older age, polypharmacy, and longer hospital stays.
Dagnew et al. (2022) conducted a cross-sectional in Psychiatric disorders (n=325). Combination of medications was evaluated on Prevalence of clinically significant potential drug-drug interactions (pDDIs). In admitted patients with psychiatric disorders, 68.9% were exposed to at least one clinically significant potential drug-drug interaction, with polypharmacy (≥5 medications) significantly increasing this risk (AOR 3.45).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: